Biologic Lung Volume Reduction
Phase 1Biologic
Biologic Lung Volume Reduction is one of 25 biologic programs targeting Emphysema. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Emphysema
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Serevent
GGlaxo Dba Glaxosmithkline
Approved
Pulmicort
SSalix
Approved
Advil
KKenvue Brands
Approved
Foradil
ViatrisApproved
Alpha1-Proteinase Inhibitor
CSL BehringApproved
Pulmicort Pmdi HFA
AstraZenecaApproved
Budesonide/formoterol
AstraZenecaPhase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AAeris Therapeutics